NCT04313023View on ClinicalTrials.gov

The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2

PHASE2CompletedINTERVENTIONAL
Enrollment

217

Participants

Timeline

Start Date

June 9, 2020

Primary Completion Date

July 31, 2021

Study Completion Date

July 31, 2021

Conditions
COVID-19
Interventions
DRUG

PUL-042 Inhalation Solution

20.3 µg Pam2 : 29.8 µg ODN/mL (50 µg PUL-042) PUL-042 Inhalation Solution

DRUG

Placebo

Sterile saline for inhalation

Trial Locations (15)

30281

Clinical Research Atlanta, Stockbridge

33134

Clinical Research of South Florida Alliance for Multispecialty Research, Coral Gables

33136

Luminous Cinical Research- South Florida Urgent Care, Miami

33156

Entrust Clinical Research, Miami

33308

Invesclinic US LLC, Fort Lauderdale

33321

DBC Research, Tamarac

33612

Affinity Clinical Research, LLC, Tampa

71111

Willis-Knighton Physcian Network, Bossier City

74006

Ascension St John, Bartlesville

74104

Ascension St. John, Tulsa

77030

MD Anderson Cancer Center, Houston

77057

Next Level Urgent Care, Houston

78539

Invesclinic US LLC, Edinburg

92404

Premier Urgent Care of California, San Bernardino

92868

University of California Irvine, Orange

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Pulmotect, Inc.

INDUSTRY

NCT04313023 - The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2 | Biotech Hunter | Biotech Hunter